Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Morgan Stanley Downgrades Vaccitech to Equal-Weight, Lowers Price Target to $3.25

Author: Benzinga Newsdesk | September 25, 2023 05:41am
Morgan Stanley analyst Matthew Harrison downgrades Vaccitech (NASDAQ:VACC) from Overweight to Equal-Weight and lowers the price target from $14 to $3.25.

Posted In: VACC


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist